复发性库欣病再次经蝶手术的疗效分析
该研究回顾2008至2018年因复发性库欣病接受再次经蝶手术的患者,当前队列15例中术后即刻缓解率86.7%,平均随访34.7个月持续缓解率68.8%。与历史队列合并后51例中即刻缓解68.6%,末次随访持续缓解60.8%,提示再次手术在放疗或药物治疗前可为有效安全选择。
要点
- 复发性库欣病再次经蝶手术术后即刻缓解率可达86.7%。
- 平均随访34.7个月,68.8%患者维持持续缓解。
- 再次手术可作为放疗或药物治疗前的有效安全选择。
核心结论
- 复发性库欣病的治疗具有挑战性,但再次经蝶手术在多数患者中可作为放疗或药物治疗前的有效且安全的下一步治疗。
研究设计与样本
- 回顾性 review,纳入2008至2018年因临床和/或生化复发库欣病接受再次经蝶手术且术后随访至少12个月的患者,当前队列15例,并与既往已发表数据合并为51例的合并队列。
主要发现
- 当前队列15例中,首次手术病理为ACTH腺瘤者13/15(86.7%),术前MRI显示复发证据者9/15(60%)。
- 当前队列术后即刻缓解13/15(86.7%),平均随访34.7个月(范围12-116个月)持续缓解11/15(68.8%)。
- 合并队列51例中,既往手术病理为ACTH腺瘤者44/51(86.3%),术前MRI显示复发证据者35/51(68.6%)。
临床怎么用
- 对于复发性库欣病患者,再次经蝶手术可在放疗或药物治疗前考虑,以期实现生化缓解。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transspheniodal surgery (TSS) for Cushing disease (CD) is considered the first-line treatment; however, reported recurrence rates are high. OBJECTIVE: To systemically review indications and outcomes for repeat TSS in recurrent CD. METHODS: Retrospective review of patients undergoing TSS from 2008 to 2018 was performed. Patients undergoing repeat TSS for clinical and/or biochemically recurrent CD with follow-up at least 12 mo postoperatively were included. These data were analyzed in our "current cohort" and combined with our previously published data in a "combined cohort." RESULTS: The current cohort of patients undergoing operations from 2008 to 2018 with repeat surgery following a prior operation included 15 patients. Pathology at the time of first operation was positive for adrenocortiotrophic hormone (ACTH) adenoma in 13/15 (86.7%) and 9/15 (60%) had evidence of recurrence after a previous surgical procedure on preoperative magnetic resonance imaging (MRI). Remission was achieved immediately postoperatively in 13/15 (86.7%). Over an average follow-up of 34.7 mo (range: 12-116), 11/15 (68.8%) achieved persistent remission. When combined with the historical cohort that underwent an operation during 1992-2006, 44/51 (86.3%) patients had a prior operation demonstrating ACTH adenoma and 35/51 (68.6%) had evidence of recurrent disease on preoperative MRI. Thirty-five (68.6%) patients went into remission immediately postoperatively. Thirty one (60.8%) had continued remission at most recent reported follow-up. CONCLUSION: Recurrent CD can be a therapeutic challenge; however, these data demonstrate that in many patients repeat surgery can be an effective and safe next step prior to radiation or medical therapy.
引用
- Burke WT, Penn DL, Repetti CS, et al. Outcomes After Repeat Transsphenoidal Surgery for Recurrent Cushing Disease: Updated. Neurosurgery. 2019. PMID: 31140553. doi:10.1093/neuros/nyz193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。